Metabolic basis of sporadic Alzeimer’s disease. Role of hormones related to energy metabolism

Current Pharmaceutical Design

Volumn 19, Issue 38, 2013, Pages 6739-6748

  Folch, Jaume ^b   Pedrós, Ignacio ^b   Patraca, Iván ^b   Martínez, Nohora ^b   Sureda, Francesc ^b   Camins, Antoni ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

Adipokines; Amylin; Ghrelin; Leptin; Prolactin; Sporadic Alzheimer disease

Indexed keywords

AMYLIN; GHRELIN; GLUCOSE; LEPTIN; PROLACTIN; ADIPOCYTOKINE;

ADIPOSE TISSUE; ALZHEIMER DISEASE; AMNESIA; ARCUATE NUCLEUS; ARTICLE; ASTROCYTE; CELL ENERGY; CELL METABOLISM; ENDOCRINE GLAND; ENERGY METABOLISM; GENE EXPRESSION; GLUCOSE METABOLISM; HUMAN; IN VITRO STUDY; INDUSTRIALIZATION; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; TRANSGENIC MOUSE; ANIMAL; BRAIN; DIABETES MELLITUS; METABOLISM; PHYSIOLOGY; REVIEW;

ADIPOKINES; ALZHEIMER DISEASE; ANIMALS; BRAIN; DIABETES COMPLICATIONS; ENERGY METABOLISM; GHRELIN; GLUCOSE; HUMANS; ISLET AMYLOID POLYPEPTIDE; LEPTIN; METABOLIC SYNDROME X;

EID: 84879270346     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990612     Document Type: Article

References (100)

1. [1] Hardy JA, Higgins GA. Alzheimer’s disease: The amyloid cascade hypothesis. Science 1992; 256: 184-5.
2. [2] Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s dis- ease: Progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
3. [3] Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer’s disease. Int J Biochem Cell Biol 2009 41: 1261-8.
4. [4] Pimplikar SW, Nixon RA, Robakis NK, Shen J, and Tsai LH. Amyloid-Independent Mechanisms in Alzheimer’s Pathogenesis. The Journal of Neuroscience, 2010 November 10, 20 30(45): 14946-54.
5. [5] Budovsky A, Abramovich A, Cohen R, Chalifa-Caspi V, Fraifeld V. Longevity network: construction and implications. Mech Ageing Dev 2007; 128(1): 117-24.
6. [6] Budovsky A, Tacutu R, Yanai H, Abramovich A, Wolfson M, Fraifeld V. Common gene signature of cancer and longevity. Mech Ageing Dev 2008; doi: 10.1016/j.mad.2008.04.002.
7. [7] Blalock EM, Chen KC, Stromberg AJ, et al. Harnessing the power of gene microarrays for the study of brain aging and Alzheimer's disease: statistical reliability and functional correlation. Ageing Res Rev 2005 Nov; 4(4): 481-512.
8. [8] Rowe WB, Blalock EM, Chen KC, et al. Hippocampal expression analyses reveal selective association of immediate-early, neu-roenergetic, and myelinogenic pathways with cognitive impairment in aged rats. J Neurosci 2007; 27(12): 3098-110.
9. [9] Kadish I, Thibault O, Blalock EM, et al. Hippocampal and Cogni- tive Aging across the Lifespan: A Bioenergetic Shift Precedes and Increased Cholesterol Trafficking Parallels Memory Impairment. J Neurosci 2009; 29(6): 1805-16.
10. [10] Lu PH, Edland SD, Teng E, et al. Alzheimer’s Disease Cooperative StudyGroup. Donepezil delays progression toAD in MCIsubjects with depressive symptoms. Neurology 2009; 72: 2115-21.
11. [11] Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006; 5: 160-70.
12. [12] Alley GM, Bailey JA, Chen D, et al. Memantine lowers amyloid-beta peptidelevels in neuronal cultures and inAPP/PS1 transgenic mice. J Neurosci Res 2010; 88: 143-54.
13. [13] Bassil N, Grossberg GT. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer’s disease. CNS Drugs 2009; 23: 293-307.
14. [14] Van der Schyf CJ, Gal S, Geldenhuys WJ, Youdim MB. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glu-tamatergic action for neurodegenerative diseases. Expert Opin In-vestig Drugs 2006; 15: 873-86.
15. [15] Shah RS, Lee HG, Xiongwei Z, et al. Current approaches in the treatment of Alzheimer’s disease. Biomed Pharmacother 2008; 62: 199-207.
16. [16] Galluzzi L, Blomgren K, Kroemer G. Mitochondrial membrana permeabilization in neuronal injury. Nat Rev Neurosci 2009; 10: 481-94.
17. [17] Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane per-meabilization in cell death. Physiol Rev 2007; 87: 99-163.
18. [18] Golde TE. et al. Targeting Abeta and tau in Alzheimer’s disease, an early interim report. Exp Neurol 2010: 223: 252-66.
19. [19] Merlo S, Spampinato S, Canonico PL, Copani A, Sortino MA. Alzheimer's disease: brain expression of a metabolic disorder?. Trends Endocrinol Metab 2010; 21(9): 537-44.
20. [20] Accardi G, Caruso C, Colonna-Romano G, Camarda C, Monastero R, Candore G. Can Alzheimer disease be a form of type 3 diabetes?. Rejuvenation Res 2012; 15(2): 217-21.
21. [21] Erol A. An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease. J Alzheimers Dis 2008; 13(3): 241-53.
22. [22] Moroz N, Tong M, Longato L, Xu H, de la Monte SM. Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimers Dis 2008; 15(1): 29-44.
23. [23] Doruk H, Naharci MI, Bozoglu E, Isik AT, Kilic S. The relationship between body mass index and incidental mild cognitive impairment, Alzheimer's disease and vascular dementia in elderly. J Nutr Health Aging 2010; 14(10): 834-8.
24. [24] Gerozissis K., Brain insulin: regulation, mechanisms of action and functions, Cell Molecul Neurobiol 2003, 23: 1-25.
25. [25] Wiesinger H, Hamprecht B, Dringen R. Metabolic pathways for glucose in astrocytes, Glia 1997; 21: 22-34.
26. [26] Magistretti PJ, Pellerin L. The contribution of astrocytes to the 18F-2-deoxyglucose signal in PET activation studies. Mol Psychiatry 1996; 1(6): 445-52.
27. [27] Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer’s disease. Ann N Y Acad Sci 2008; 1147: 180-95.
28. [28] Scheef L, Spottke A, Daerr M, et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology 2012; 79(13): 1332-9.
29. [29] Mamelak M. Sporadic Alzheimer's disease: the starving brain. J Alzheimers Dis 2012; 31(3): 459-74.
30. [30] Bouzier-Sore AK, Voisin P, Bouchaud V, Bezancon E, Franconi JM, Pellerin L. Competition between glucose and lactate as oxidative energy substrates in both neurons and astrocytes: a comparative NMR study, Eur J Neurosci 2006, 24: 1687-94.
31. [31] Greco SJ, Hamzelou A, Johnston JM, Smith MA, Ashford JW, Tezapsidis N. Leptin boosts cellular metabolism by activating AMPK and the sirtuins to reduce tau phosphorylation and |3-amyloid in neurons. Biochem Biophys Res Commun 2011; 414(1): 170-4.
32. [32] Young JY. Anatomical relationship between specialized astrocytes and leptin-sensitive neurones. J. Anat 2002 201: 85-90.
33. [33] Gahete MD, Rubio A, Córdoba-Chacón J, et al. Expression of the ghrelin and neurotensin systems is altered in the temporal lobe of Alzheimer's disease patients. J Alzheimers Dis 2010; 22(3): 819-28.
34. [34] Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481.
35. [35] Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444: 847-53.
36. [36] Mazaki-Tovi S, Kanety H, Pariente C, et al. Insulin sensitivity in late gestation and early postpartum period: the role of circulating maternal adipokines. Gynecol Endocrinol 2011; 27(9): 725-31.
37. [37] Ballantyne GH, Gumbs A, Modlin IM. Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obes Surg 2005; 15(5): 692-9.
38. [38] Kieffer TJ, Habener JF. The adipoinsular axis: effects of leptin on pancreatic beta-cells. Am J Physiol Endocrinol Metab 2000; 278: E1-E14.
39. [39] Kim JB, Wright M, Yao KM, et al. Nutritional and insulin regulation of fatty acid synthase and leptin gene expression through ADD1/SREBP1. J Clin Invest 1998 101: 1-9.
40. [40] Henquin JC, Meissner HP Opposite effects of tolbutamide and diazoxide on 86 Rb+ fluxes and membrane potential in pancreatic B cells. Biochem Pharmacol 1982 31: 1407-15.
41. [41] Alemzadeh R, Tushaus KM. Modulation of adipoinsular axis in prediabetic zucker diabetic fatty rats by diazoxide. Endocrinology 2004; 145(12): 5476-84.
42. [42] Faust IM, Johnson PR, Hirsch J. Surgical removal of adipose tissue alters feeding behavior and the development of obesity in rats. Science 1977; 197: 393-6.
43. [43] Schneider BS, Faust IM, Hemmes R, Hirsch J. Effects of altered adipose tissue morphology on plasma insulin levels in the rat. Am J Physiol 1981; 240: E358-62.
44. [44] Söderberg S, Ahrén B, Eliasson M, Dinesen B, Olsson T. The association between leptin and proinsulin is lost with central obesity. J Intern Med 2002; 252(2): 140-8.
45. [45] Hartter E, Svoboda T, Ludvik B, et al. Basal and stimulated plasma levelsof pancreatic amylin indicate itsco-secretion with insulin in humans. Diabetologia 1991; 34: 52-54.
46. [46] Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Li-narelli LG. Amylin concentrations and glucose control. Lancet 1992; 339: 1179-80.
47. [47] Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 1999; 892: 146-54.
48. [48] Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adi-pokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13: 84-9.
49. [49] Schwartz MW, Morton GJ. Obesity: keeping hunger at bay. Nature 2002 Aug 8; 418(6898): 595-7.
50. [50] Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 1978; 3: 141-8.
51. [51] Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreac-tive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-5.
52. [52] Staiger H, Tschritter O, Macham J et al. Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res 2003; 11: 368-72.
53. [53] Greco SJ, Sarkar S, Casadesus G, et al. Leptin inhibits glycogen synthase kinase-3beta to prevent tauphosphorylation in neuronal cells. Neurosci Lett 2009; 455: 191-4.
54. [54] Marwarha G, Dasari B, Prabhakara JP, Schommer J, Ghribi O. |3-Amyloid regulates leptin expression and tau phosphorylation through the mTORC1 signaling pathway. J Neurochem 2010; 115(2): 373-84.
55. [55] Marwarha G, Dasari B, Prasanthi JR, Schommer J, Ghribi O. Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27 hydroxycholesterol in rabbit organotypic slices. J Alzheimers Dis 2010; 19(3): 1007-19.
56. [56] Luo W, Bodary PF, Shen Y, et al. Leptin receptor-induced STAT3-independent signaling pathways are protective against atherosclerosis in a murine model of obesity and hyperlipidemia. Atherosclerosis 2011; 214(1): 81-5.
57. [57] Greco SJ, Sarkar S, Johnston JM, et al. Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells. Biochem Biophys Res Commun 2008; 376(3): 536-41.
58. [58] Greco SJ, Sarkar S, Johnston JM, Tezapsidis N. Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem Biophys Res Commun 2009; 380(1): 98-104.
59. [59] De Vriese C, Delporte C. Influence of ghrelin on food intake and energy homeostasis. Curr Opin Clin Nutr Metab Care 2007; 10: 615-9.
60. [60] Theodoropoulou A, Metallinos IC, Psyrogiannis A, Vagenakis GA, Kyriazopoulou V. Ghrelin and leptin secretion in patients with moderate Alzheimer's disease. J Nutr Health Aging 2012; 16(5): 472-7.
61. [61] Diano S, Farr SA, Benoit SC, et al. Ghrelin controls hippocampal spine synapse density and memory performance. Nat Neurosci 2006 9: 381-8.
62. [62] Cai H, Cong WN, Ji S, Rothman S, Maudsley S, Martin B. Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr Alzheimer Res 2012; 9(1): 5-17.
63. [63] Cai Z, Yan LJ, Li K, Quazi SH, Zhao B. Roles of AMP-activated protein kinase in Alzheimer's disease. Neuromolecular Med 2012; 14(1): 1-14.
64. [64] Hou Z, Miao Y, Gao L, Pan H, Zhu S. Ghrelin-containing neuron in cerebral cortex and hypothalamus linked with the DVC of brainstem in rat. Regul Pept 2006; 134: 126-31.
65. [65] Guan XM, Yu H, Palyha OC, et al. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 1997; 48: 23-9.
66. [66] Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-8.
67. [67] Carlini VP, Monzon ME, Varas MM, et al. Ghrelin increases anxiety-like behavior and memory retention in rats. Biochem Biophys Res Commun 2002; 299: 739-43.
68. [68] Ma L, Zhang D, Dong-min MS, et al. Ghrelin-Attenuated Cognitive Dysfunction in Streptozotocin-induced Diabetic Rats. Alzheimer Disease & Associated Disorders 2011; 25(4): 352-63.
69. [69] Giordano V, Peluso G, Iannuccelli M, Benatti P, Nicolai R, Calvani M. Systemic and brain metabolic dysfunction as a new paradigm for approaching Alzheimer's dementia. Neurochem Res 2007 32: 555-67.
70. [70] Cong WN, Golden E, Pantaleo N, White CM, Maudsley S, Martin B. Ghrelin receptor signaling: a promising therapeutic target for metabolic syndrome and cognitive dysfunction. CNS Neurol Disord Drug Targets 2010 9: 557-63.
71. [71] Young A, Pittner R, Gedulin B, Vine W, Rink T. Amylin regulation of carbohydrate metabolism. Biochem Soc Trans 1995; 23(2): 325-31.
72. [72] Gedulin BR, Rink TJ, Young AA. Dose-response for gluca-gonostatic effect of amylin in rats. Metabolism 1997; 46: 67-70.
73. [73] Price CJ, Hoyda TD, Ferguson AV. The area postrema: a brain monitor and integrator of systemic autonomic state. Neuroscientist 2008; 14(2): 182-94.
74. [74] Riediger T, Schmid HA, Lutz TA, Simon E. Amylin and glucose co-activate area postrema neurons of the rat. Neurosci Lett 2002; 328(2): 121-4.
75. [75] Christopoulos G, Perry KJ, Morfis M, et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 1999; 56(1): 235-42.
76. [76] Tilakaratne N, Christopoulos G, Zumpe ET, Foord SM, Sexton PM. Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. J Pharmacol Exp Ther 2000; 294(1): 61-72.
77. [77] Fu W, Ruangkittisakul A, MacTavish D, Shi JY, Ballanyi K, Jhamandas JH. Amyloid p (A|3) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways. J Biol Chem 2012; 287(22): 18820-30.
78. [78] Jhamandas JH, Li Z, Westaway D, Yang J, Jassar S, MacTavish D. Actions of |3-amyloid protein on human neurons are expressed through the amylin receptor. Am J Pathol 2011; 178(1): 140-9.
79. [79] Turek VF, Trevaskis JL, Levin BE, Dunn-Meynell AA, Irani B, Gu G, Wittmer C, Griffin PS, Vu C, Parkes DG, Roth JD. Mechanisms of amylin/leptin synergy in rodent models. Endocrinology 2010; 151(1): 143-52.
80. [80] Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in dietinduced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 2008; 105(20): 7257-62.
81. [81] Roth JD, Maier H, Chen S, Roland BL. Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. Arch Neurol 2009; 66(3): 306-10.
82. [82] Moon HS, Chamberland JP, Diakopoulos KN, et al. Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans. Diabetes Care 2011; 34(1): 132-8.
83. [83] Trevaskis JL, Parkes DG, Roth JD. Insights into amylin-leptin synergy. Trends Endocrinol Metab 2010; 21(8): 473-9.
84. [84] Agostinho P, Cunha RA, Oliveira C. Neuroinflammation,oxidative stress and the pathogenesis of Alzheimer’s disease. Curr Pharm Des 2010, 16, 2766-78.
85. [85] Farfara, D., Lifshitz, V., Frenkel, D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer’s disease. J Cell Mol Med 2008; 12: 762-80.
86. [86] Azizi G, Mirshafiey A. The potential role of proinflammatory and antiinflammatory cytokines in Alzheimer disease pathogenesis. Immunopharmacol Immunotoxicol 2012; 34(6): 881-95.
87. [87] De Simoni MG, Perego C, Ravizza T, et al. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosci 2000; 12: 2623-33.
88. [88] Vezzani A, Conti M, De Luigi A, et al. Interleukin-1beta im-munoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J Neurosci 1999; 19: 5054-65.
89. [89] Vezzani A, Moneta D, Conti M, et al. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc Natl Acad SciUS A 2000; 97: 11534-9.
90. [90] Ravizza T, Rizzi M, Perego C, et al. Inflammatory response and glia activation in developing rat hippocampus after status epilepticus. Epilepsia 2005; 46 Suppl 5: 113-7.
91. [91] Erbayat Altay E, Fessler AJ, Gallagher M, et al. Correlation of severity of FDG-PET hypometabolism and interictal regional delta slowing in temporal lobe epilepsy. Epilepsia 2005; 46(4): 573-6.
92. [92] Guo Z, Jiang H, Xu X, Duan W, Mattson MP. Leptin-mediated cell survival signaling in hippocampal neurons mediated by JAK STAT3 and mitochondrial stabilization. J Biol Chem 2008; 283(3): 1754-63.
93. [93] Dicou E, Attoub S, Gressens P. Neuroprotective effects of leptin in vivo and in vitro. Neuroreport 2001; 12(18): 3947-51.
94. [94] Lee J, Lim E, Kim Y, Li E, Park S. Ghrelin attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. J Endocrinol 2010; 205(3): 263-70.
95. [95] Biagini G, Torsello A, Marinelli C, et al. Beneficial effects of desacyl-ghrelin, hexarelin and EP-80317 in models of status epilepticus. Eur J Pharmacol 2011; 670(1): 130-6.
96. [96] Tejadilla D, Cerbón M, Morales T. Prolactin reduces the damaging effects of excitotoxicity in the dorsal hippocampus of the female rat independently of ovarian hormones. Neuroscience 2010; 169(3): 1178-85.
97. [97] Phelps CJ, Romero MI, Hurley DL. Prolactin replacement must be continuous and initiated prior to 21 d of age to maintain hypotha-lamic dopaminergic neurons in hypopituitary mice. Endocrine 2003; 20: 139-48.
98. [98] Furuta M, Bridges RS. Gestation-induced cell proliferation in the rat brain. Brain Res Dev Brain Res 2005 156: 61-6.
99. [99] Mangoura D, Pelletiere C, Leung S, Sakellaridis N, Wang DX. Prolactin concurrently activates src-PLD and JAK/Stat signaling pathways to induce proliferation while promoting differentiation in embryonic astrocytes. Int J Dev Neurosci 2000 18: 693-704.
100. [100] Torner L, Karg S, Blume A, et al. Prolactin prevents chronic stress-induced decrease of adult hippocampal neurogenesis and promotes neuronal fate. J Neurosci 2009 29: 1826-33.